search
Back to results

HPV Self-testing in Transgender Individuals (Self-TI)

Primary Purpose

HPV Infection

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
HPV DNA methylation assay
Sponsored by
Queen Mary University of London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for HPV Infection focused on measuring Transgender, Trans men, Trans women, Non-binary individuals

Eligibility Criteria

21 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria for trans men and non-binary adults with a cervix: Identify as transgender or non-binary Be between 25 - 65 years of age Be registered with a general practitioner Have an intact cervix Have used testosterone therapy within the last year Be willing, and able to understand and consent to study procedures Inclusion Criteria for trans women and non-binary adults : Identify as transgender or non-binary Be 18 years of age or older Have undergone vaginoplasty by any method at least 1 year ago Be willing, and able to understand and consent to study procedures Exclusion Criteria: Have a variation of sex characteristics (also known as a disorder of sex development) Have an allergy to any of the ingredients in the oral rinse (Scope) Be diagnosed with, or under investigation for, an inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease). This does not include irritable bowel syndrome - participants with this are eligible to enroll. Be a member of a vulnerable population, which includes pregnant people, fetuses, children, prisoners, or anyone unable to independently offer consent.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Other

    Experimental

    Arm Label

    Trans men and non-binary people with a cervix

    Trans women and non-binary people

    Arm Description

    Participants will have a clinician-collected cervical screening sample and then collect the following self-samples for research: Vaginal swab, Anal swab, Oral rinse, and Urine sample for the detection of HPV detection.

    Participants will collect the following self-samples for research in the clinic: Vaginal swab, Anal swab, Oral rinse, and Urine sample for the detection of HPV detection. Participants will collect the following self-samples for research at home: Vaginal swab, Anal swab, and Oral rinse sample for the detection of HPV detection.

    Outcomes

    Primary Outcome Measures

    Feasibility of self-sampling in clinic
    Feasibility of self-sampling in clinic as measured by the proportion of completed and returned self-samples.
    Acceptability of self-sampling in clinic
    Acceptability of self-sampling in clinic as indicated by high satisfaction on an online survey
    Feasibility of self-sampling at home
    Feasibility of self-sampling at home as measured by the proportion of completed and returned self-samples.
    Acceptability of self-sampling at home
    Acceptability of self-sampling at home as indicated by high satisfaction on an online survey

    Secondary Outcome Measures

    HPV concordance between vaginal self-sample and clinician-collected cervical swab
    Concordance HPV positivity, overall and by genotype, from self-collected vaginal samples to clinician-collected cervical samples in trans men and nonbinary adults with a cervix.
    HPV correlation between self-samples taken at clinic and in home among trans women and non-binary people.
    HPV correlation between self-samples taken at clinic and in-home among trans women and non-binary people.

    Full Information

    First Posted
    April 24, 2023
    Last Updated
    May 22, 2023
    Sponsor
    Queen Mary University of London
    Collaborators
    National Cancer Institute (NCI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05883111
    Brief Title
    HPV Self-testing in Transgender Individuals
    Acronym
    Self-TI
    Official Title
    HPV Methylation Self-testing Pilot in Transgender Individuals
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 1, 2023 (Anticipated)
    Primary Completion Date
    October 1, 2024 (Anticipated)
    Study Completion Date
    October 2028 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Queen Mary University of London
    Collaborators
    National Cancer Institute (NCI)

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Human papillomavirus (HPV) is a common virus that spreads through skin-to-skin contact. Some HPV types can cause changes in cells that lead to cancer and are known as 'high-risk' HPV (hrHPV). hrHPV is linked to cancers of the cervix (opening of the womb), throat, and anus (exit of the bowel). It is not known if transgender people (individuals whose gender identity does not align with their sex assigned at birth) are at increased risk of hrHPV or cancers caused by hrHPV compared to cisgender people (individuals whose gender identity does align with their birth sex). There is also little knowledge about HPV in the vagina for transgender women who have surgery to make one. Transgender men may be at higher risk of cervical cancer than cisgender women because they are less likely to go for screening. This can be because of physical discomfort and emotional distress during screening when a swab is taken directly from the cervix. The investigators seek to examine how common hrHPV is in transgender people in different parts of the body. In the study, participants will take swabs from the vagina and anus, a urine sample, and use mouthwash. Transgender men will also have an extra swab taken by a clinician as part of routine cervical screening. This is to see if the swab from the vagina is as good as the one from the cervix for finding cells that might lead to cancer. Participants will also take an online survey to measure the acceptability of self-sampling compared to clinician sampling. This research can inform HPV prevalence and decision-making about HPV screening among transgender people.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    HPV Infection
    Keywords
    Transgender, Trans men, Trans women, Non-binary individuals

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    100 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Trans men and non-binary people with a cervix
    Arm Type
    Other
    Arm Description
    Participants will have a clinician-collected cervical screening sample and then collect the following self-samples for research: Vaginal swab, Anal swab, Oral rinse, and Urine sample for the detection of HPV detection.
    Arm Title
    Trans women and non-binary people
    Arm Type
    Experimental
    Arm Description
    Participants will collect the following self-samples for research in the clinic: Vaginal swab, Anal swab, Oral rinse, and Urine sample for the detection of HPV detection. Participants will collect the following self-samples for research at home: Vaginal swab, Anal swab, and Oral rinse sample for the detection of HPV detection.
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    HPV DNA methylation assay
    Intervention Description
    HPV DNA methylation assay to detect HPV positivity, HPV genotype, and HPV methylation.
    Primary Outcome Measure Information:
    Title
    Feasibility of self-sampling in clinic
    Description
    Feasibility of self-sampling in clinic as measured by the proportion of completed and returned self-samples.
    Time Frame
    Baseline
    Title
    Acceptability of self-sampling in clinic
    Description
    Acceptability of self-sampling in clinic as indicated by high satisfaction on an online survey
    Time Frame
    Baseline
    Title
    Feasibility of self-sampling at home
    Description
    Feasibility of self-sampling at home as measured by the proportion of completed and returned self-samples.
    Time Frame
    1 month follow-up
    Title
    Acceptability of self-sampling at home
    Description
    Acceptability of self-sampling at home as indicated by high satisfaction on an online survey
    Time Frame
    1 month follow up
    Secondary Outcome Measure Information:
    Title
    HPV concordance between vaginal self-sample and clinician-collected cervical swab
    Description
    Concordance HPV positivity, overall and by genotype, from self-collected vaginal samples to clinician-collected cervical samples in trans men and nonbinary adults with a cervix.
    Time Frame
    Baseline
    Title
    HPV correlation between self-samples taken at clinic and in home among trans women and non-binary people.
    Description
    HPV correlation between self-samples taken at clinic and in-home among trans women and non-binary people.
    Time Frame
    Baseline and 1 month follow up
    Other Pre-specified Outcome Measures:
    Title
    HPV correlation between self-samples at each site
    Description
    HPV correlation between self-samples at each site (vaginal, anal, oral, and urine) in each arm.
    Time Frame
    Baseline and 1 month follow up
    Title
    Performance of HPV methylation assay
    Description
    Comparison of the performance of HPV methylation testing from self-collected samples to clinician-collected samples for the detection of cervical precancer in trans men and non-binary adults with a cervix.
    Time Frame
    Baseline

    10. Eligibility

    Sex
    All
    Gender Based
    Yes
    Gender Eligibility Description
    Transgender and gender diverse identities.
    Minimum Age & Unit of Time
    21 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion criteria for trans men and non-binary adults with a cervix: Identify as transgender or non-binary Be between 25 - 65 years of age Be registered with a general practitioner Have an intact cervix Have used testosterone therapy within the last year Be willing, and able to understand and consent to study procedures Inclusion Criteria for trans women and non-binary adults : Identify as transgender or non-binary Be 18 years of age or older Have undergone vaginoplasty by any method at least 1 year ago Be willing, and able to understand and consent to study procedures Exclusion Criteria: Have a variation of sex characteristics (also known as a disorder of sex development) Have an allergy to any of the ingredients in the oral rinse (Scope) Be diagnosed with, or under investigation for, an inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease). This does not include irritable bowel syndrome - participants with this are eligible to enroll. Be a member of a vulnerable population, which includes pregnant people, fetuses, children, prisoners, or anyone unable to independently offer consent.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Alison M Berner
    Phone
    44 7738 011636
    Email
    a.m.berner@qmul.ac.uk
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Sarah S Jackson, PhD
    Organizational Affiliation
    National Cancer Institute (NCI)
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Alison M Berner, MBBS, PhD
    Organizational Affiliation
    Queen Mary University of London
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    HPV Self-testing in Transgender Individuals

    We'll reach out to this number within 24 hrs